KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Net (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Receivables - Net for 15 consecutive years, with $187.8 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 32.18% to $187.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $187.8 million through Dec 2025, up 32.18% year-over-year, with the annual reading at $187.8 million for FY2025, 32.18% up from the prior year.
  • Receivables - Net for Q4 2025 was $187.8 million at Supernus Pharmaceuticals, up from $171.3 million in the prior quarter.
  • The five-year high for Receivables - Net was $187.8 million in Q4 2025, with the low at $127.1 million in Q1 2021.
  • Average Receivables - Net over 5 years is $149.0 million, with a median of $145.3 million recorded in 2022.
  • The sharpest move saw Receivables - Net fell 13.61% in 2023, then soared 32.18% in 2025.
  • Over 5 years, Receivables - Net stood at $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then fell by 12.9% to $144.2 million in 2023, then fell by 1.44% to $142.1 million in 2024, then soared by 32.18% to $187.8 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $187.8 million, $171.3 million, and $140.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.